newsfilter
← Latest News
ACCESS Newswire·

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

MIRA
  • MIRA Pharmaceuticals announced new preclinical data on Mira-55, a cannabinoid analog in development for chronic inflammatory pain.
  • Mira-55 acts through a distinct pharmacological mechanism compared to THC & does not produce central nervous system side effects.
  • Unlike THC, Mira-55 demonstrated anxiolytic activity by reducing anxiety-like behavior in animal testing.
  • Standard THC-like tests showed Mira-55 caused only a modest drop in body temperature, with no effects on movement or muscle rigidity.
  • The CB1 antagonist rimonabant reversed THC's effects but did not block Mira-55's impact on body temperature, confirming a different mechanism of action.
  • Mira-55 delivered pain relief comparable to morphine in inflammatory pain models without opioid-related risks.
  • The U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance.
  • MIRA plans to advance Mira-55 toward an Investigational New Drug (IND) submission for chronic inflammatory pain.
  • Current treatment options for inflammatory pain include opioids with dependence risks & NSAIDs with gastrointestinal, renal, & cardiovascular adverse effects.
  • MIRA's pipeline also includes Ketamir-2 for neuropathic pain & SKNY-1 for obesity & smoking cessation.